WO1999035167A1 - Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide - Google Patents
Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide Download PDFInfo
- Publication number
- WO1999035167A1 WO1999035167A1 PCT/FR1998/002899 FR9802899W WO9935167A1 WO 1999035167 A1 WO1999035167 A1 WO 1999035167A1 FR 9802899 W FR9802899 W FR 9802899W WO 9935167 A1 WO9935167 A1 WO 9935167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rheumatoid arthritis
- antigen
- filaggrin
- serum
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Definitions
- PEPTIDE EPITOPES RECOGNIZED BY ANTIFILAGGRIN AUTOANTIBODIES PRESENT IN THE SERUM OF PATIENTS WITH RHUMATOID POLYARTHRITIS.
- the present invention relates to new preparations of antigens specifically recognized by auto-antibodies specific for rheumatoid arthritis.
- RA Rheumatoid arthritis
- RA Rheumatoid arthritis
- serum of affected patients contains autoantibodies, some of which are specific, and can constitute a marker of this disease, allowing its diagnosis even at early stages.
- Research has therefore been carried out with a view to identifying antigens recognized by these antibodies, in order to obtain purified preparations which can be used in conventional techniques of immunological diagnosis.
- the inventors obtained, from human and murine squamous epithelia, preparations of antigens related to filaggrin and to profilaggrin, recognized specifically by the antibodies present in the serum of patients suffering from rheumatoid arthritis, and showed that the "antibodies antikeratins "were in fact anti-filaggrin autoantibodies (hereinafter referred to as" AAF ").
- Application EP 0 511 116 describes these antigenic preparations, and their use for the diagnosis of rheumatoid arthritis.
- Filaggrins are a family of proteins which has been identified in various species, notably in humans, rats, mice, guinea pigs, in the case of squamous keratinizing epithelia [for a review on filaggrins, cf. DALE et al. [The Keratinocyte Handbook, Cambridge University Press, pp 323-350, (1994)]. They derive from the dephosphorylation and proteolysis of a precursor, profilaggrin, which consists essentially of repeating domains of filaggrin separated by peptide segments between domains.
- the gene coding for profilaggrin consists of repeated subunits, each of which codes for a filaggrin molecule, separated by portions coding for the interdomain peptide segments. All the repeating units coding for each of the human filaggrins have the same length (972 base pairs in humans); however, in humans, there are significant variations (10-15%) in sequence from one subunit to another. While most are conservative, some of these variations induce changes in amino acids and in some cases changes in the electrical charge of the protein. Thus human filaggrins form, independently of post-transcriptional modifications, a heterogeneous population of molecules of similar size but of different sequences and charges (pHi equal to 8.3 ⁇ 1.1) [GAN et al., Bioche. 29, p. 9432-9440 (1990)].
- Profilaggrin is a high molecular weight protein (approximately 400,000 in humans) soluble in the presence of high concentrations of salts or urea. It has a high content of basic amino acids (arginine and histidine), as well as glycine, serine and glutamic acid. It is poor in non-polar amino acids and contains neither methionine, cysteine, nor tryptophan. It is strongly phosphorylated on Serine residues, which gives it an isoelectric point close to neutrality.
- Filaggrins resulting from dephosphorylation and from cleavage of profilaggrin are basic proteins whose amino acid content is similar to that of profilaggrins. They participate in the organization of the keratin filaments, and undergo a progressive maturation during which the arginine residues, basic, are converted into citrulline residues, neutral, under the action of peptidylarginine deiminase [HARDING CR and SCOTT IR, J Mol. Biol. 170, p. 651-673 (1983)]. This leads to a reduction in their affinity for the keratins from which they are detached; they are then completely degraded under the action of various proteases.
- the properties of filaggrins and profilaggrins have been particularly well studied in rats, mice and humans.
- the size of profilaggrin varies, depending on the species, from 300 to 400 kD and that of filaggrins from 27 to 64 kD.
- Filaggrins also exhibit great inter- and intra-specific variability in their sequence. However, this variability does not affect their functional properties, their overall amino acid composition, and their biochemical properties. Likewise, the tissue localizations of profilaggrin and filaggrins are identical in the different mammals studied.
- the inventors sought to reproduce in vi tro, from recombinant filaggrin, these post-translational modifications, in order to determine which were liable to influence the antigenicity of filaggrin.
- This work resulted in the obtaining of artificial antigens recognized specifically by the FAAs present in the serum of RA patients, and constituted by recombinant or synthetic polypeptides, derived from the sequence of filaggrin, or portions of that -ci, by substitution of at least one arginine residue by a citrulline residue.
- filamentaggrin unit means a polypeptide whose sequence is that of the translation product of any of the subunits coding for a filaggrin domain of the gene for human profilaggrin or of another species, or else is a consensus sequence, theoretical sequence obtained from the sequences of the filaggrin domains.
- these epitopes comprise a tripeptide motif centered on a citrulline residue, specifically present on citrulline peptides derived from the sequences SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, and absent from the sequence SEQ ID NO: 4.
- the present invention relates to a peptide constituting an epitope recognized by anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid arthritis, characterized in that said epitope comprises a tripeptide motif centered on a citrulline residue, specifically present on at least one of the citrullinated peptides derived from the sequences SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6.
- said peptide comprises at least one pentapeptide motif centered on a citrulline residue, present on at least one of the citrulline peptides derived from the sequences SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6.
- said peptide comprises the tripeptide motif Ser-Cit-His, in which Cit represents a citrulline residue.
- the peptides in accordance with the invention allow the preparation of artificial antigens recognized specifically by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid arthritis. These artificial antigens are also part of the object of the present invention.
- Artificial antigens according to the invention comprise at least one peptide epitope centered on a citrulline residue, as defined above. They are for example constituted by peptides of at least 5 amino acids, preferably at least 10 amino acids, and advantageously at least 14 amino acids.
- They may be peptides consisting of at least one fragment of at least one of the citrullinated peptides derived from the sequences SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, or containing at least one such fragment.
- These peptides can comprise several citrullinated epitopes specifically recognized by AAF, of identical or different sequences.
- peptide as used in the present Application means in particular protein or protein fragment, oligopeptide, extract, separated or substantially isolated or synthesized, in particular those obtained by chemical synthesis or by expression in a recombinant organism; any peptide in the sequence of which one or more amino acids of the L series are replaced by an amino acid of the D series, and vice versa; any peptide of which at least one of the CO-NH bonds, and advantageously all of the CO-NH bonds of the peptide chain is (are) replaced by one (of) NH-CO bonds; any peptide of which at least one of the CO-NH bonds and advantageously all of the CO-NH bonds is or are replaced by one or more NH-CO bonds, the chirality of each aminoacyl residue, whether either involved or not in one or more CO-NH bonds mentioned above, being either conserved or reversed with respect to the aminoacyl residues constituting a reference peptide, these compounds being also designated immunoretroids, a mimotope, etc.
- Antigens according to the invention can for example be obtained by the action of PAD (peptidyl arginine deiminase) on proteins or peptides natural, recombinant, or synthetic, comprising arginine residues, and in particular comprising at least one arginine residue constituting the center of a tripeptide motif identical to those present in the sequences SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6; they can also be obtained by peptide synthesis, by directly incorporating one or more citrulline residues, and preferably one or more epitopes comprising a citrulline residue, as defined above, in the synthesized peptide.
- PAD peptidyl arginine deiminase
- the present invention also relates to the use of the antigens in accordance with the invention, as defined above, for the in vi tro diagnosis of RA.
- the present invention encompasses in particular antigenic compositions for diagnosing the presence of RA-specific autoantibodies in a biological sample, which compositions are characterized in that they contain at least one antigen according to the invention, optionally labeled and / or conjugated with a carrier molecule.
- the present invention also relates to a method for detecting RA specific class G autoantibodies in a biological sample, which method is characterized in that it comprises:
- This detection method can be implemented using a kit comprising at least one antigen according to the invention, as well as buffers and reagents suitable for constituting a medium. reaction allowing the formation of an antigen / antibody complex, and / or means of detection of said antigen / antibody complex.
- Said kit may also include, where appropriate, reference samples, such as one or more negative serum (s) and one or more positive serum (s).
- reference samples such as one or more negative serum (s) and one or more positive serum (s).
- EXAMPLE 1 IN VITRO DEIMINATION OF RECOMBINANT FILAGGRIN BY PEPTIDYL ARGININE DEIMINASE (P.A.D.).
- Recombinant filaggrin is produced according to the following protocol:
- a DNA fragment coding for a filaggrin unit is amplified by PCR, from human genomic DNA (RAJI cells: ATCC CCL86) using the following 2 primers: 5 'primer:
- the amplification product is cloned into the SmaI site of the vector pUC19.
- the recombinant clones are selected, checking the presence of a 972 bp insert obtained after digestion with SacI and Xbal.
- This insert is then subcloned into pUC19.
- the insert resulting from this subcloning is then transferred into the vector pGEX (sold by the company PHARMACIA), between the EcoRI and HindIII sites.
- the expression vector thus obtained expresses, in E. coli, filaggrin in fusion with glutathione-S-transferase (GST), under the control of the prokaryotic promoter Tac.
- the mixture of the 9 fragments is subjected to in vitro elimination by peptidyl arginine deiminase.
- a preparation of rabbit muscle peptidyl arginine deiminase (681 U / ml) sold by TAKARA BIOMED EUROPE is used, according to the protocol recommended by the manufacturer.
- the operating conditions are as follows:
- BSA bovine serum albumin
- PHAST ® -SDS 12.5% gel, PHARMACIA electrophoresis gel
- electrophoresis is carried out with the PHAST-SYSTEM ® device (PHARMACIA), under the conditions recommended by the manufacturer.
- nitrocellulose either with a pool of 5 sera from RA patients, diluted to 1/2000, or with the anti-filaggrin monoclonal antibody AHF2 [SIMON et al. J. Invest. Dermatol. 105, 432, (1995)] at the concentration of 0.2 ⁇ g / ml.
- the antigen / antibody complex is revealed using a secondary antibody coupled to peroxidase, by the ECL technique.
- the peptide of 49 amino acids S-47-S of sequence (code 1 letter): NH 2 -STGHSGSQHSHTTTQGRSDASRGSSGSRSTSRETRDQEQSGDGSRHSGS-COOH corresponding to amino acids 71 to 119 of the sequence of a human filaggrin unit, and comprising 6 arginine residues, and the peptide of 37 amino acids S-35-R of sequence (code 1 letter):
- the peptides S-47-S and S-35-R are represented in the sequence list in the appendix under the respective numbers SEQ ID NO: 3 and SEQ ID NO: 4.
- Peptides E-12-H and E-12-0 were determined by reference to the nucleotide sequences of the human profilaggrin gene described by GAN S.Q et al. [Biochemistry, 29: 9432-9440, (1990)].
- NH 2 -EQSADSSRHSGSGH-COOH comprises 1 arginine residue, and the peptide of 14 amino acids E-12-D of sequence (code 1 letter):
- NH 2 -ESSRDGSRHPRSHD-COOH contains 3 arginine residues.
- the peptides E-12-H and E-12-D are represented in the sequence list in the appendix under the respective numbers SEQ ID NO: 5 and SEQ ID NO: 6.
- citrullinated peptides E-12-H and E-12-D were synthesized directly by incorporation of a citrulline in replacement of an arginine.
- the wells of NUNC MAXISORP microtiter plates were coated respectively with the non-citrullinated and citrullinated peptides E-12-D and E-12-H, diluted to a concentration of 5 ⁇ g / ml in PBS buffer (pH : 7.4) and incubated overnight at 4 ° C (final volume: 100 ⁇ g / well).
- the wells were saturated for 30 minutes at 37 ° C. in PBS-T een 20, 0.05% gelatin 2.5%, 200 ⁇ l / well.
- the negative control serum normal serum was diluted 1/120.
- anti-filaggrin antibodies were diluted in PBS-Tween 20, 0.05% - 0.5% gelatin (PBS TG) so that the final concentrations of anti-filaggrin autoantibody are those indicated in Table I attached.
- Negative control serum, PR sera and anti-filaggrin antibodies were added (final volume: 100 ⁇ l / well) and incubated for 1 hour at 37 ° C and overnight at 4 ° C.
- Goat anti-heavy chain gamma antibodies of human immunoglobulins labeled with peroxidase (marketed by the company SOUTHERN BIOTECHNOLOGIES) were added to each well (dilution in PBSTG: 1/2000, final volume: 100 ⁇ l / well) and subjected incubation for 1 hour at 37 ° C. The revelation was carried out by adding orthophenylenediamine (2 mg / ml, for 10 minutes).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98964536A EP1042366A1 (fr) | 1997-12-30 | 1998-12-29 | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
CA002316269A CA2316269A1 (fr) | 1997-12-30 | 1998-12-29 | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
AU19717/99A AU1971799A (en) | 1997-12-30 | 1998-12-29 | Peptide epitopes recognised by antifilaggrin autoantibodies in serum from rheumatoid arthritis patients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/16673 | 1997-12-30 | ||
FR9716673A FR2773157B1 (fr) | 1997-12-30 | 1997-12-30 | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999035167A1 true WO1999035167A1 (fr) | 1999-07-15 |
Family
ID=9515272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/002899 WO1999035167A1 (fr) | 1997-12-30 | 1998-12-29 | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1042366A1 (fr) |
AU (1) | AU1971799A (fr) |
CA (1) | CA2316269A1 (fr) |
FR (1) | FR2773157B1 (fr) |
WO (1) | WO1999035167A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826124A1 (fr) * | 2001-06-13 | 2002-12-20 | Bio Merieux | Procede de detection d'auto-anticorps specifiques de la polyarthrite rhumatoide |
EP1041997B1 (fr) * | 1997-12-30 | 2003-04-16 | Universite Paul Sabatier (Toulouse Iii) | Utilisation de peptides citrullines derives de la filaggrine dans le cadre du traitement de maladies autoimmunes |
WO2003050542A2 (fr) * | 2001-12-11 | 2003-06-19 | Stichting Voor De Technische Wetenschappen | Procede pour detecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoide, peptide et trousse de dosage |
EP1980855A1 (fr) | 2004-02-27 | 2008-10-15 | Roche Diagnostics GmbH | Méthode d'évaluation de la polyarthrite rhumatoide consistant à mesurer la concentration d'anti-CCP et de sérum amyloide A |
US7846674B2 (en) | 2003-12-23 | 2010-12-07 | Roche Diagnostics Operations, Inc. | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 |
EP2336769A1 (fr) | 2009-12-18 | 2011-06-22 | F. Hoffmann-La Roche AG | Test pour différencier les troubles rhumatismaux des troubles non rhumatismaux |
US8058013B2 (en) | 2006-09-29 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Assessing risk of disease progression in rheumatoid arthritis patients |
EP3056903A1 (fr) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Procédé d'évaluation de l'arthrite rhumatoïde par la mesure de l'anti-CCP et de l'anti-Casp8 |
EP3056904A1 (fr) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Procédé pour l'évaluation de l'arthrite rhumatoïde par la mesure de l'anti-CCP et de l'anti-MCM3 |
WO2016128348A1 (fr) | 2015-02-13 | 2016-08-18 | F. Hoffmann-La Roche Ag | Procédé d'évaluation de la polyarthrite rhumatoïde par mesure des anti-ccp et anti-pik3cd |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2391356A1 (fr) * | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides permettant de diagnostiquer et de traiter la polyarthrite rhumatoide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008946A1 (fr) * | 1996-08-30 | 1998-03-05 | Biomerieux | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
-
1997
- 1997-12-30 FR FR9716673A patent/FR2773157B1/fr not_active Expired - Fee Related
-
1998
- 1998-12-29 AU AU19717/99A patent/AU1971799A/en not_active Abandoned
- 1998-12-29 WO PCT/FR1998/002899 patent/WO1999035167A1/fr not_active Application Discontinuation
- 1998-12-29 EP EP98964536A patent/EP1042366A1/fr not_active Withdrawn
- 1998-12-29 CA CA002316269A patent/CA2316269A1/fr not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008946A1 (fr) * | 1996-08-30 | 1998-03-05 | Biomerieux | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 128, no. 12, 23 March 1998, Columbus, Ohio, US; abstract no. 139653, G A SCHELLEKENS ET AL.: "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific antibodies" XP002101365 * |
E GIRBAL-NEUHAUSER ET AL.: "The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (Pro)filaggrin b deimidation of arginine residues", JOURNAL OF IMMUNOLOGY, vol. 162, no. 1, 1 January 1999 (1999-01-01), BALTIMORE US, pages 585 - 594, XP002101364 * |
J. CLIN. INVEST., vol. 101, no. 1, 1 January 1998 (1998-01-01), pages 273 - 281 * |
SCHELLEKENS G A ET AL: "THE MODIFIED ARGININE RESIDUE CITRULLINES IS THE MAJOR CONSTITUENT OF EPITOPES RECOGNIZED BY AUTOANTIBODIES IN SERA FROM RHEUMATOID ARTHRITIS PATIENTS", ARTHRITIS AND RHEUMATISM, vol. 40, no. 9, SUPPL. 08, 8 November 1997 (1997-11-08), pages S276, XP002067877 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1041997B1 (fr) * | 1997-12-30 | 2003-04-16 | Universite Paul Sabatier (Toulouse Iii) | Utilisation de peptides citrullines derives de la filaggrine dans le cadre du traitement de maladies autoimmunes |
FR2826124A1 (fr) * | 2001-06-13 | 2002-12-20 | Bio Merieux | Procede de detection d'auto-anticorps specifiques de la polyarthrite rhumatoide |
WO2003050542A3 (fr) * | 2001-12-11 | 2003-12-11 | Stichting Tech Wetenschapp | Procede pour detecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoide, peptide et trousse de dosage |
US7888133B2 (en) | 2001-12-11 | 2011-02-15 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
US9689871B2 (en) | 2001-12-11 | 2017-06-27 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
EP1693673A2 (fr) * | 2001-12-11 | 2006-08-23 | Stichting Voor De Technische Wetenschappen | Procédé pour détecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoïde |
EP1693673A3 (fr) * | 2001-12-11 | 2006-12-06 | Stichting Voor De Technische Wetenschappen | Procédé pour détecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoïde |
CN105699648B (zh) * | 2001-12-11 | 2017-10-20 | 技术科学基金会 | 从患有类风湿性关节炎的患者中检测自身抗体的方法、肽和检测试剂盒 |
CN105699648A (zh) * | 2001-12-11 | 2016-06-22 | 技术科学基金会 | 从患有类风湿性关节炎的患者中检测自身抗体的方法、肽和检测试剂盒 |
NL1019540C2 (nl) * | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit. |
US10119966B2 (en) | 2001-12-11 | 2018-11-06 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and assay kit |
US8759114B2 (en) | 2001-12-11 | 2014-06-24 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
WO2003050542A2 (fr) * | 2001-12-11 | 2003-06-19 | Stichting Voor De Technische Wetenschappen | Procede pour detecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoide, peptide et trousse de dosage |
US8481332B2 (en) | 2001-12-11 | 2013-07-09 | Stichting Voor de Technische Wetenshappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
US7846674B2 (en) | 2003-12-23 | 2010-12-07 | Roche Diagnostics Operations, Inc. | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 |
US8062907B2 (en) | 2004-02-27 | 2011-11-22 | Roche Diagnostics Operations, Inc. | Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A |
US7981693B2 (en) | 2004-02-27 | 2011-07-19 | Roche Diagnostics Operations, Inc. | Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritis |
EP1980855A1 (fr) | 2004-02-27 | 2008-10-15 | Roche Diagnostics GmbH | Méthode d'évaluation de la polyarthrite rhumatoide consistant à mesurer la concentration d'anti-CCP et de sérum amyloide A |
US8058013B2 (en) | 2006-09-29 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Assessing risk of disease progression in rheumatoid arthritis patients |
EP2336769A1 (fr) | 2009-12-18 | 2011-06-22 | F. Hoffmann-La Roche AG | Test pour différencier les troubles rhumatismaux des troubles non rhumatismaux |
WO2016128348A1 (fr) | 2015-02-13 | 2016-08-18 | F. Hoffmann-La Roche Ag | Procédé d'évaluation de la polyarthrite rhumatoïde par mesure des anti-ccp et anti-pik3cd |
EP3056904A1 (fr) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Procédé pour l'évaluation de l'arthrite rhumatoïde par la mesure de l'anti-CCP et de l'anti-MCM3 |
EP3056903A1 (fr) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Procédé d'évaluation de l'arthrite rhumatoïde par la mesure de l'anti-CCP et de l'anti-Casp8 |
US10094826B2 (en) | 2015-02-13 | 2018-10-09 | Roche Diagnostics Operations, Inc. | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD |
Also Published As
Publication number | Publication date |
---|---|
CA2316269A1 (fr) | 1999-07-15 |
EP1042366A1 (fr) | 2000-10-11 |
AU1971799A (en) | 1999-07-26 |
FR2773157B1 (fr) | 2001-10-05 |
FR2773157A1 (fr) | 1999-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0929669B1 (fr) | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide | |
EP1814901B1 (fr) | Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyartrhite rhumatoide, et leurs utilisations | |
EP0423301B1 (fr) | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a | |
EP1196450B1 (fr) | Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumato de | |
WO1999035167A1 (fr) | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide | |
EP0451070B1 (fr) | Procédé d'identification ou de dosage de protéines et applications | |
EP1204865B1 (fr) | Composes synthetiques portant deux epitopes pour immunodosages | |
FR2677653A1 (fr) | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. | |
WO2021070696A1 (fr) | Peptide cyclique possédant une activité inhibitrice de ctla-4, et application de celui-ci | |
CA2204438A1 (fr) | Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation | |
EP0491014B1 (fr) | PEPTIDES DE L'ANTIGENE Sm-D ET LEUR UTILISATION NOTAMMENT POUR LE DIAGNOSTIC DU LUPUS ERYTHEMATEUX DISSEMINE | |
US10913780B2 (en) | Conjugates, their compositions, their uses, and their methods of making | |
FR2682113A1 (fr) | Peptides issus de la proteine a de la ribonucleoproteine snrnp-u1 et leur utilisation pour le diagnostic de la connectivite mixte. | |
FR2798672A1 (fr) | Formes acides des peroxyredoxines et leur utilisation comme moyen de diagnostic | |
FR2826124A1 (fr) | Procede de detection d'auto-anticorps specifiques de la polyarthrite rhumatoide | |
FR2848566A1 (fr) | Peptides epitopiques de l'enzyme thyroperoxydase, les compositions les contenant et leurs applications | |
EP1423708A1 (fr) | Compositions et methodes pour le dosage de l'aa4rp | |
EP0252787A1 (fr) | Polypeptides de surfaces cellulaires, isolés et purifiés, reconnus par les anticorps responsables de la pathogénie du lupus érythémateux disséminé (LED), leur méthode d'obtention et leur application au diagnostic du LED |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2316269 Country of ref document: CA Ref country code: CA Ref document number: 2316269 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09582711 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998964536 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998964536 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998964536 Country of ref document: EP |